Form 4: Corcept Therapeutics Director Daniel N. Swisher Jr. Executes Stock Option and Sells Shares
SEC Form 4
Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold shares on March 10, 2025, according to a Form 4 filing with the SEC.
Summary
- On March 10, 2025, Daniel N. Swisher Jr., a director of Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
- Simultaneously, Swisher sold 2,200 shares of common stock at $53.60 per share.
- The sale was executed under a pre-arranged 10b5-1 trading plan adopted on August 1, 2024.
- Following these transactions, Swisher directly owns 0 shares of Corcept Therapeutics common stock.
- Swisher also holds 4,000 stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider trading activity, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives and directors to have pre-arranged trading plans (10b5-1 plans) to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the director's sale of shares, but the overall impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of adoption of 10b5-1 trading plan |
| 03/10/2025 | Date of stock option exercise and share sale |
| 05/24/2027 | Expiration date of stock options |
| 03/12/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.